

Ramaswamy Govindan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2079201/publications.pdf>

Version: 2024-02-01

206
papers

19,204
citations

41627

51
h-index

14779

131
g-index

209
all docs

209
docs citations

209
times ranked

29491
citing authors

#	ARTICLE	IF	CITATIONS
1	Point of care tobacco treatment sustains during COVID-19, a global pandemic. <i>Cancer Epidemiology</i> , 2022, 78, 102005.	0.8	8
2	Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. <i>Lung Cancer</i> , 2022, 166, 270-278.	0.9	21
3	Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10 ⁺ advanced non-small cell lung cancer. , 2022, 10, e003581.		19
4	Targeting KRAS G12C mutation in lung adenocarcinoma. <i>Lung Cancer</i> , 2022, 165, 28-33.	0.9	10
5	Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 214-225.	1.1	14
6	Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 856132.	1.3	2
7	Reply to G. Bi et al. <i>Journal of Clinical Oncology</i> , 2022, 40, 1260-1260.	0.8	0
8	Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy. <i>Cancers</i> , 2022, 14, 1910.	1.7	9
9	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. <i>NAR Cancer</i> , 2022, 4, zcac014.	1.6	7
10	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
11	A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9148-TPS9148.	0.8	2
12	Trends in stage I lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10508-10508.	0.8	0
13	A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 337-347.	1.1	5
14	Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL. <i>Lung Cancer</i> , 2021, 151, 25-29.	0.9	4
15	Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2021, 10, 826-838.	1.3	5
16	Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. <i>Cell Reports</i> , 2021, 34, 108707.	2.9	16
17	Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism. <i>Journal of Clinical Oncology</i> , 2021, 39, 697-700.	0.8	3
18	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. <i>Journal of Clinical Oncology</i> , 2021, 39, 1349-1359.	0.8	147

#	ARTICLE	IF	CITATIONS
19	A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3630-3640.	3.2	11
20	Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRAS ^{G12C} inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreak 101).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2669-TPS2669.	0.8	7
21	Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5600-TPS5600.	0.8	3
22	Cause of death among patients with non-small cell lung cancer treated with postoperative radiation therapy (PORT).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20555-e20555.	0.8	1
23	Overall survival and exploratory subgroup analyses from the phase 2 CodeBreak 100 trial evaluating sotorasib in pretreated KRAS ^{G12C} mutated non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9003-9003.	0.8	18
24	Sotorasib for Lung Cancers with KRAS ^{G12C} Mutation. <i>New England Journal of Medicine</i> , 2021, 384, 2371-2381.	13.9	833
25	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). <i>Immunotherapy</i> , 2021, 13, 727-734.	1.0	11
26	A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. <i>Journal of Thoracic Disease</i> , 2021, 13, 4054-4062.	0.6	9
27	Overcoming Chemotherapy Resistance in SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2002-2015.	0.5	39
28	Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3391-3402.	0.8	320
29	Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3633-3644.	0.8	27
30	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , 2021, 12, 5086.	5.8	58
31	Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. <i>Journal of Clinical Oncology</i> , 2021, 39, 3747-3758.	0.8	38
32	Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer. <i>Cancer Cell</i> , 2020, 38, 320-322.	7.7	5
33	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. <i>Cell</i> , 2020, 183, 347-362.e24.	13.5	349
34	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). <i>Journal of Thoracic Oncology</i> , 2020, 15, 1748-1757.	0.5	21
35	KRAS ^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217.	13.9	1,049
36	Sex and gender: modifiers of health, disease, and medicine. <i>Lancet</i> , 2020, 396, 565-582.	6.3	955

#	ARTICLE	IF	CITATIONS
37	Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2020, 16, 749-762.	1.1	0
38	Long non-coding RNA LCAL62 / LINC00261 is associated with lung adenocarcinoma prognosis. <i>Heliyon</i> , 2020, 6, e03521.	1.4	13
39	Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. <i>Cell</i> , 2020, 182, 200-225.e35.	13.5	410
40	The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy. <i>JAMA Oncology</i> , 2020, 6, 674.	3.4	7
41	Whole Exome Sequencing of Highly Aggregated Lung Cancer Families Reveals Linked Loci for Increased Cancer Risk on Chromosomes 12q, 7p, and 4q. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 434-442.	1.1	11
42	Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014. <i>BMC Endocrine Disorders</i> , 2020, 20, 44.	0.9	14
43	nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+). <i>Frontiers in Oncology</i> , 2020, 10, 569715.	1.3	3
44	278â€¦Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer. , 2020, 8, A303-A303.		3
45	Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3011-3011.	0.8	1
46	Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3661-TPS3661.	0.8	8
47	ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9077-TPS9077.	0.8	18
48	Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9080-TPS9080.	0.8	5
49	Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 75-75.	0.8	3
50	Role of the total mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) on the development of second primary cancer after complete resection of non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21092-e21092.	0.8	0
51	Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21080-e21080.	0.8	0
52	A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer (NSCLC) (NCT02299141).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21694-e21694.	0.8	0
53	Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 6119-6126.	3.2	28
54	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. <i>Nature</i> , 2019, 575, 217-223.	13.7	1,375

#	ARTICLE	IF	CITATIONS
55	Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1828-1838.	0.5	50
56	Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. <i>Current Medical Research and Opinion</i> , 2019, 35, 1761-1767.	0.9	1
57	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4888-4897.	3.2	181
58	Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	24
59	Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 701-711.	0.5	41
60	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-104.	0.8	159
61	Open-Sourced CIVIC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-12.	1.0	6
62	Biomarker-Driven Staging—Are We There Yet?. <i>JAMA Network Open</i> , 2019, 2, e1917052.	2.8	1
63	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 25-36.	0.5	68
64	Accounting for proximal variants improves neoantigen prediction. <i>Nature Genetics</i> , 2019, 51, 175-179.	9.4	43
65	Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. <i>Journal of Clinical Oncology</i> , 2019, 37, 2601-2601.	0.8	2
66	JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2019, 37, 9009-9009.	0.8	74
67	Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC). <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8577-TPS8577.	0.8	11
68	Non-Small-Cell Lung Cancer With Brain Metastasis at Presentation. <i>Clinical Lung Cancer</i> , 2018, 19, e373-e379.	1.1	162
69	Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> , 2018, 173, 355-370.e14.	13.5	620
70	Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 543-549.	0.5	15
71	The association of weight change in young adulthood and smoking status with risk of prostate cancer recurrence. <i>International Journal of Cancer</i> , 2018, 142, 2011-2018.	2.3	3
72	Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. <i>Modern Pathology</i> , 2018, 31, 791-808.	2.9	79

#	ARTICLE	IF	CITATIONS
73	Predictors of Follow-Up Visits Post Radical Prostatectomy. American Journal of Men's Health, 2018, 12, 760-765.	0.7	10
74	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2995-3006.	0.8	223
75	A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data. Nature Genetics, 2018, 50, 1735-1743.	9.4	62
76	The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. Cancer Causes and Control, 2018, 29, 1143-1150.	0.8	3
77	ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Cancer, 2018, 124, 4667-4675.	2.0	12
78	Targeting Resistance to Targeted Therapies: Combating a Resilient Foe. Clinical Cancer Research, 2018, 24, 6112-6114.	3.2	3
79	Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nature Communications, 2018, 9, 3787.	5.8	112
80	The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC. Journal of Thoracic Oncology, 2018, 13, 1183-1188.	0.5	12
81	The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes and Control, 2018, 29, 685-697.	0.8	4
82	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
83	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
84	Barriers and Strategies to Participation in Tissue Research Among African-American Men. Journal of Cancer Education, 2017, 32, 51-58.	0.6	19
85	An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer, 2017, 104, 126-130.	0.9	33
86	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. British Journal of Cancer, 2017, 116, 1505-1512.	2.9	25
87	Systemic Treatment of Brain Metastases. Hematology/Oncology Clinics of North America, 2017, 31, 157-176.	0.9	8
88	Next-Generation Sequencing of Lung Cancers. Hematology/Oncology Clinics of North America, 2017, 31, 1-12.	0.9	12
89	African American prostate cancer survivorship: Exploring the role of social support in quality of life after radical prostatectomy. Journal of Psychosocial Oncology, 2017, 35, 409-423.	0.6	24
90	Physician role in physical activity for African-American males undergoing radical prostatectomy for prostate cancer. Supportive Care in Cancer, 2017, 25, 1151-1158.	1.0	10

#	ARTICLE	IF	CITATIONS
91	EVALUATING COMMUNITY ENGAGEMENT IN RESEARCH: QUANTITATIVE MEASURE DEVELOPMENT. Journal of Community Psychology, 2017, 45, 17-32.	1.0	45
92	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1552-1560.	0.5	75
93	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2017, 35, 3449-3457.	0.8	311
94	Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. Journal of Clinical Oncology, 2017, 35, 2885-2892.	0.8	68
95	Incidence of Cancer in Spinal Deformity Patients Receiving High-Dose (40mg) Bone Morphogenetic Protein (rhBMP-2). Spine, 2017, 42, 1785-1791.	1.0	10
96	Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2017, 35, 4074-4074.	0.8	18
97	An open-label, phase Ib study of NEO-PV-01 + adjuvant with nivolumab in patients with melanoma, non-small cell lung carcinoma, or transitional cell carcinoma of the bladder.. Journal of Clinical Oncology, 2017, 35, TPS3116-TPS3116.	0.8	1
98	Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.. Journal of Clinical Oncology, 2017, 35, 2553-2553.	0.8	0
99	Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).. Journal of Clinical Oncology, 2017, 35, TPS3096-TPS3096.	0.8	2
100	Secondary consent to biospecimen use in a prostate cancer biorepository. BMC Research Notes, 2016, 9, 346.	0.6	6
101	Obesity and Other Cancers. Journal of Clinical Oncology, 2016, 34, 4231-4237.	0.8	44
102	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nature Genetics, 2016, 48, 607-616.	9.4	933
103	Clinical Implications of Genomic Discoveries in Lung Cancer. New England Journal of Medicine, 2016, 374, 1864-1873.	13.9	235
104	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 4079-4085.	0.8	171
105	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. Journal of Thoracic Oncology, 2016, 11, 1387-1396.	0.5	6
106	Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC. Journal of Thoracic Oncology, 2016, 11, 1729-1735.	0.5	74
107	Delayed nausea and vomiting from carboplatin doublet chemotherapy. Acta Oncologica, 2016, 55, 700-704.	0.8	6
108	Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. Journal of Clinical Oncology, 2016, 34, 661-668.	0.8	548

#	ARTICLE	IF	CITATIONS
109	Differences in preferences for models of consent for biobanks between Black and White women. <i>Journal of Community Genetics</i> , 2016, 7, 41-49.	0.5	17
110	Somatic mutations in mismatch repair pathway genes in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11523-11523.	0.8	2
111	Prevalence, clinical risk factors and outcomes of patients with lung cancer presenting with brain metastases.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2075-2075.	0.8	1
112	A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. cooperative group trials: Comparing the outcomes of elderly to younger patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8508-8508.	0.8	2
113	Circulating cell-free tumor DNA (cfDNA) testing in small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23077-e23077.	0.8	1
114	Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA8505-LBA8505.	0.8	9
115	CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8579-TPS8579.	0.8	20
116	Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA8505-LBA8505.	0.8	13
117	Stage III pulmonary large cell neuroendocrine carcinoma (LNEC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8536-8536.	0.8	1
118	Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20507-e20507.	0.8	1
119	Clinical characteristics and treatment outcomes of patients with pulmonary salivary gland-like tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8534-8534.	0.8	0
120	Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8529-8529.	0.8	0
121	A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous cell lung cancer (SqCLC) previously treated with platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9101-TPS9101.	0.8	2
122	Effects of Vitamin D Supplementation on C-peptide and 25-hydroxyvitamin D Concentrations at 3 and 6 Months. <i>Scientific Reports</i> , 2015, 5, 10411.	1.6	7
123	Non-Small Cell Lung Cancer, Version 6.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 515-524.	2.3	323
124	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5439-5444.	3.2	104
125	Patterns and functional implications of rare germline variants across 12 cancer types. <i>Nature Communications</i> , 2015, 6, 10086.	5.8	243
126	Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: A systematic review of completed and ongoing studies. <i>Lung Cancer</i> , 2015, 87, 232-240.	0.9	23

#	ARTICLE	IF	CITATIONS
127	Mammograms on-the-go—predictors of repeat visits to mobile mammography vans in St Louis, Missouri, USA: a case-control study. <i>BMJ Open</i> , 2015, 5, e006960-e006960.	0.8	14
128	Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 200-208.	1.1	6
129	Clonal Evolution: Multiregion Sequencing of Esophageal Adenocarcinoma Before and After Chemotherapy. <i>Cancer Discovery</i> , 2015, 5, 796-798.	7.7	4
130	Genomic alterations in lung adenocarcinoma. <i>Lancet Oncology</i> , The, 2015, 16, e342-e351.	5.1	302
131	Repeatability of ¹⁸ F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1137-1143.	2.8	79
132	Overcoming Resistance to Targeted Therapy for Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1760-1761.	13.9	24
133	A Community Coalition to Address Cancer Disparities: Transitions, Successes and Challenges. <i>Journal of Cancer Education</i> , 2015, 30, 616-622.	0.6	20
134	Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 2100-2105.	0.8	150
135	Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. <i>European Respiratory Journal</i> , 2015, 46, 1751-1761.	3.1	37
136	Bone Metastases in Lung Cancer. Potential Novel Approaches to Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 799-809.	2.5	26
137	A Community-Based Partnership to Successfully Implement and Maintain a Breast Health Navigation Program. <i>Journal of Community Health</i> , 2015, 40, 1216-1223.	1.9	19
138	Impact of vitamin D supplementation on adiposity in African-Americans. <i>Nutrition and Diabetes</i> , 2015, 5, e147-e147.	1.5	4
139	Clinical next-generation sequencing in patients with non-small cell lung cancer. <i>Cancer</i> , 2015, 121, 631-639.	2.0	190
140	Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7506-7506.	0.8	10
141	Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8008-8008.	0.8	18
142	ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS7583-TPS7583.	0.8	3
143	Use of chemotherapy for patients with stage IV non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19010-e19010.	0.8	0
144	A phase I study of temsirolimus plus erlotinib in patients with refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2600-2600.	0.8	9

#	ARTICLE	IF	CITATIONS
145	Adjuvant chemotherapy for patients with T2N0M0 non-small cell lung cancer.. Journal of Clinical Oncology, 2015, 33, 7520-7520.	0.8	1
146	Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future. Journal of Thoracic Disease, 2015, 7, 217-9.	0.6	0
147	Null Association between Vitamin D and PSA Levels among Black Men in a Vitamin D Supplementation Trial. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1944-1947.	1.1	22
148	Impact of Vitamin D Supplementation on Inflammatory Markers in African Americans: Results of a Four-Arm, Randomized, Placebo-Controlled Trial. Cancer Prevention Research, 2014, 7, 218-225.	0.7	75
149	The oligometastatic stateâ€”separating truth from wishful thinking. Nature Reviews Clinical Oncology, 2014, 11, 549-557.	12.5	245
150	<i>TP53</i> Mutations and Lung Cancer: Not All Mutations Are Created Equal. Clinical Cancer Research, 2014, 20, 4419-4421.	3.2	25
151	Summary Report From the 13th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. Clinical Lung Cancer, 2014, 15, 16-20.	1.1	1
152	Risk of Hypercalcemia in Blacks Taking Hydrochlorothiazide and Vitamin D. American Journal of Medicine, 2014, 127, 772-778.	0.6	10
153	A Phase I Study of Temozolomide and Thoracic Radiation in Nonâ€”Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 119-123.	1.1	20
154	Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial. American Journal of Clinical Nutrition, 2014, 99, 587-598.	2.2	62
155	Attack of the clones. Science, 2014, 346, 169-170.	6.0	21
156	cDNA Hybrid Capture Improves Transcriptome Analysis on Low-Input and Archived Samples. Journal of Molecular Diagnostics, 2014, 16, 440-451.	1.2	40
157	Perceived barriers to mammography among underserved women in a Breast Health Center Outreach Program. American Journal of Surgery, 2014, 208, 425-434.	0.9	57
158	CHESS improves cancer caregiversâ€™ burden and mood: Results of an eHealth RCT.. Health Psychology, 2014, 33, 1261-1272.	1.3	121
159	BRCAness in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 11033-11033.	0.8	5
160	Postoperative radiotherapy (PORT) for pathologic N2 non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy: A review of the National Cancer Database.. Journal of Clinical Oncology, 2014, 32, 7509-7509.	0.8	1
161	SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.. Journal of Clinical Oncology, 2014, 32, 7514-7514.	0.8	35
162	NLG-0301: An open-label, randomized phase 2B active control study of second-line terigenpumatucel-L immunotherapy versus docetaxel in patients with progressive or relapsed non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, TPS8133-TPS8133.	0.8	3

#	ARTICLE	IF	CITATIONS
163	Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.. Journal of Clinical Oncology, 2014, 32, TPS2644-TPS2644.	0.8	0
164	MicroRNA landscape in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, e22194-e22194.	0.8	0
165	Characteristics of 1q amplification in adenocarcinoma of the lung (LUAD).. Journal of Clinical Oncology, 2014, 32, e22195-e22195.	0.8	1
166	Advanced NSCLC: Finding the right prescription for oncologist education.. Journal of Clinical Oncology, 2014, 32, 8115-8115.	0.8	0
167	Comparing strategies to assess multiple behavior change in behavioral intervention studies. Translational Behavioral Medicine, 2013, 3, 114-121.	1.2	19
168	Molecular profile of lung cancer in never smokers. European Journal of Cancer, Supplement, 2013, 11, 248-253.	2.2	30
169	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	9.4	492
170	Effect of Vitamin D Supplementation on Blood Pressure in Blacks. Hypertension, 2013, 61, 779-785.	1.3	190
171	Impact of Obesity on Cancer Survivorship and the Potential Relevance of Race and Ethnicity. Journal of the National Cancer Institute, 2013, 105, 1344-1354.	3.0	118
172	âœDonâ€™t Knowâ€™ Responses to Risk Perception Measures. Medical Decision Making, 2013, 33, 271-281.	1.2	69
173	Optimising therapy for EGFR-addicted NSCLC: just the start. Lancet Oncology, The, 2012, 13, 216-217.	5.1	2
174	Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers. Cell, 2012, 150, 1121-1134.	13.5	1,038
175	Vitamin D and mammographic breast density: a systematic review. Cancer Causes and Control, 2012, 23, 1-13.	0.8	20
176	Phase I/II dose-finding study of crizotinib (CRIZ)âin combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 2610-2610.	0.8	8
177	Comprehensive genomic characterization of squamous cell carcinoma of the lung.. Journal of Clinical Oncology, 2012, 30, 7006-7006.	0.8	9
178	Patient-reported outcomes from POINTBREAK: The randomized, open-label, phase III study of pemetrexed (pem) + carboplatin (cb) + bevacizumab (bev) followed by maintenance pem + bev versus paclitaxel (pac) + cb + bev followed by maintenance bev in patients with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC).. Journal of Clinical Oncology, 2012, 30, 53-53.	0.8	2
179	A dose-escalation phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: Dose escalation with an intermittent 28 days on/14 days off schedule.. Journal of Clinical Oncology, 2012, 30, 3046-3046.	0.8	1
180	Hope without hype: EML4-ALK inhibition for treatment of lung cancer. Lancet Oncology, The, 2011, 12, 983-984.	5.1	3

#	ARTICLE	IF	CITATIONS
181	Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 790-795.	0.5	16
182	Summary of Presentation from the Targeted Therapy in Lung Cancer Meeting. <i>Journal of Thoracic Oncology</i> , 2011, 6, S1757.	0.5	3
183	Social and clinical predictors of prostate cancer treatment decisions among men in South Carolina. <i>Cancer Causes and Control</i> , 2011, 22, 1597-1606.	0.8	12
184	Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407. <i>Journal of Clinical Oncology</i> , 2011, 29, 3120-3125.	0.8	186
185	Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey. <i>Journal of Thoracic Oncology</i> , 2010, 5, 29-33.	0.5	437
186	Summary of the Proceedings from the 10th Annual Meeting of Molecularly Targeted Therapy in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, S433.	0.5	4
187	A Review of Epidermal Growth Factor Receptor/HER2 Inhibitors in the Treatment of Patients With Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 8-12.	1.1	22
188	Racial differences in the perception of lung cancer. <i>Cancer</i> , 2010, 116, 1981-1986.	2.0	30
189	Successful subject recruitment for a prostate cancer behavioral intervention trial. <i>Clinical Trials</i> , 2010, 7, 411-417.	0.7	19
190	Assessing Cancer Prevention Studies—A Matter of Time. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2152.	3.8	9
191	A Computer-Tailored Intervention to Promote Informed Decision Making for Prostate Cancer Screening Among African American Men. <i>American Journal of Men's Health</i> , 2009, 3, 340-351.	0.7	34
192	Locally Advanced Non-small Cell Lung Cancer: The Past, Present, and Future. <i>Journal of Thoracic Oncology</i> , 2008, 3, 917-928.	0.5	71
193	Lung Cancer in Never Smokers: A Review. <i>Journal of Clinical Oncology</i> , 2007, 25, 561-570.	0.8	587
194	Efficacy and safety of gefitinib in chemo-naïve patients with advanced non-small cell lung cancer treated in an Expanded Access Program. <i>Lung Cancer</i> , 2006, 53, 331-337.	0.9	15
195	Home- and Community-Based Service Use by Older African American, Hispanic, and Non-Hispanic White Women and Men. <i>Home Health Care Services Quarterly</i> , 2006, 25, 129-153.	0.3	18
196	Phase II Trial of Bexarotene Capsules in Patients With Advanced Non-Small-Cell Lung Cancer After Failure of Two or More Previous Therapies. <i>Journal of Clinical Oncology</i> , 2006, 24, 4848-4854.	0.8	30
197	Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database. <i>Journal of Clinical Oncology</i> , 2006, 24, 4539-4544.	0.8	1,607
198	A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. <i>Oncology Reports</i> , 2006, 15, 123-7.	1.2	0

#	ARTICLE	IF	CITATIONS
199	Chemotherapy for metastatic NSCLC: current status and future direction. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 238-239.	4.3	1
200	Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B. <i>Clinical Cancer Research</i> , 2005, 11, 2300-2304.	3.2	250
201	Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. <i>Seminars in Oncology</i> , 2004, 31, 27-31.	0.8	12
202	Cetuximab in Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4241s-4244s.	3.2	41
203	Management of patients with non-small cell lung cancer and poor performance status. <i>Current Treatment Options in Oncology</i> , 2003, 4, 55-59.	1.3	9
204	Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer. <i>Oncology</i> , 2003, 17, 27-9.	0.4	2
205	Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. <i>Oncology</i> , 2003, 17, 27-31.	0.4	5
206	Inhibitory Anti-Factor V Antibodies Bind to the Factor V C2 Domain and Are Associated With Hemorrhagic Manifestations. <i>Blood</i> , 1998, 91, 4188-4196.	0.6	4